Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
Restricted accessResearch articleFirst published online June, 2017
Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
To determine whether there is an association between higher vancomycin trough concentrations and attainment of a calculated area under the concentration–time curve (AUC)/minimum inhibitory concentration (MIC) ≥400.
Methods:
A retrospective analysis was conducted among vancomycin-treated adult patients with a positive methicillin-resistant Staphylococcus aureus (MRSA) culture. Attainment of a calculated AUC/MIC ≥400 was compared between patients with troughs in the reference range of 15 to 20 mg/L and those with troughs in the following ranges: <10, 10 to 14.9, and >20 mg/L. Nephrotoxicity was assessed as a secondary outcome based on corrected average vancomycin troughs over 10 days of treatment.
Results:
Overall, 226 patients were reviewed and 100 included. Relative to troughs ≥10, patients with vancomycin troughs <10 mg/L were 73% less likely to attain an AUC/MIC ≥400 (odds ratio [OR] 0.27, 95% confidence interval [CI]: 0.01-0.75). No difference was found in the attainment of an AUC/MIC ≥400 in patients with troughs of 10 to 14.9 mg/L and >20 mg/L when compared to patients with troughs of 15 to 20 mg/L. The mean corrected average vancomycin trough was higher in patients developing nephrotoxicity compared to those who did not (19.5 vs 14.5 mg/L, P < .001).
Conclusion:
Achieving vancomycin serum trough concentrations of 15 to 20 mg/L did not result in an increased attainment of the AUC/MIC target relative to troughs of 10 to 14.9 mg/L but may increase nephrotoxicity risk.
RybakMLomaestroBRotschaferJC. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98.
2.
Moise-BroderPAForrestABirminghamMC. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925–942.
3.
KullarRDavisSLLevineDP. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52(8):975–981.
4.
GhoshNChavadaRMaleyM. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Microbiol Infect. 2014;20(12):O1098–O1105.
5.
BrownJBrownKForrestA. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012;56(2):634–638.
6.
HolmesNETurnidgeJKMunckhofW. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–1663.
7.
LodiseTPDrusanoGLZasowskiE. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?Clin Infect Dis. 2014;59(5):666–675.
8.
HsuDIHidayatLKQuistR. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32(5):378–385.
9.
ZelenitskySRubinsteinEArianoR. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41(3):255–260.
10.
ChungJOhJMChoEM. Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth Intens Care. 2011;39(6):1030–1037.
11.
HermsenEDHansonMSankaranarayananJ. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9(1):9–14.
JeffresMNIsakowWDohertyJA. Predictors of mortality for methicillin-resistant Staphylococcus aureus healthcare-associated pneumonia: specific evaluation of pharmacokinetic indices. Chest. 2006;130(4):947–955.
14.
KralovicovaKSpanikSHalkoJ. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?J Chemother. 1997;9(6):420–426.
15.
LodiseTPGravesJEvansA. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315–3320.
16.
ZimmermannAEKatonaBGPlaisanceKI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy. 1995;15(1):85–91.
17.
Van HalSJPatersonDLLodiseTP. Systematic review and meta analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(1):734–44.
18.
SakoulasGGoldHSCohenRA. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006;57(2):699–704.
19.
RodvoldKABlumRAFischerJH. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32(6):848–852.
20.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
21.
WinterMAGuhrKNBergGM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy. 2012;32(7):604–612.
22.
LimaTMEliasSCEstrelaRC. Implementation of vancomycin dosing nomogram in an electronic prescribing system: an innovative tool in antibiotic stewardship. Braz J of Pharm Sci. 2014;50:567–572.
23.
PerroneRDMadiasNELeveyAS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933–1953.
24.
WessonLG. Renal hemodynamics in physiologic states. In: WessonLG, ed. Physiology of the Human Kidney. New York: Grune & Stratton; 1969:96–108.
25.
DaviesDFShockNW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29(5):496–507.
26.
MartinJHNorrisRBarrasM. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21–24.
27.
CheongJYMakmor-BakryMLauCL. The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients. S Afr Med J. 2012;102(7):616–619.
28.
MinejimaEChoiJBeringerP. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011;55(7):3278–3283.
29.
NeelyMNYounGJonesB. Are vancomycin trough concentrations adequate for optimal dosing?Antimicrob Agents Chemother. 2014;58(1):309–316.
30.
LeJBradleyJSMurrayW. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(suppl 4):e155–e163.
31.
FrymoyerAHershALEl-KomyMH. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014;58(11):6454–6461.
32.
TsujiBTRybakMJLauKL. Evaluation of accessory gene regulator group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(3):1089–1091.
33.
PritchardLBakerCLeggettJ. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123(12):1143–1149.
34.
BossoJANappiJRudisillC. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multi-center trial. Antimicrob Agents Chemother. 2011;55(12):5475–5479.
35.
HoreyAMergenhagenKAMattappallilA. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysis. Ann Pharmacother. 2012;46(11):1477–1483.
36.
LodiseTPPatelNLomaestroBM. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–14.
37.
WunderinkRGNiedermanMSKollefMH. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–9.
38.
JodlowskiTZSymDMazilianoA. A survey of pharmacists in academia on the current practice of estimation of kidney function for antimicrobial dosing in adults. J Pharm Pract. 2016;29(4):382–5.
39.
PatelNPaiMPRodvoldKA. Vancomycin: we can’t get there from here. Clin Infect Dis. 2011;52(8):969–974.
40.
MatsonKLShafferCLBeckGL. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and the development of nephrotoxicity in children: a multicenter retrospective study. Pharmacotherapy. 2015;35(3):337–343.
